Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 0.6% – Here’s Why

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN)’s stock price traded up 0.6% during trading on Monday . The company traded as high as $3.28 and last traded at $3.22. 20,180 shares traded hands during mid-day trading, a decline of 29% from the average session volume of 28,300 shares. The stock had previously closed at $3.20.

Analysts Set New Price Targets

Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of “Sell”.

Cyclerion Therapeutics Stock Down 4.0%

The company has a market capitalization of $13.60 million, a P/E ratio of -2.31 and a beta of 1.78. The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $2.19.

Cyclerion Therapeutics (NASDAQ:CYCN) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($17.20) by $16.44. Cyclerion Therapeutics had a negative net margin of 170.11% and a negative return on equity of 62.10%. Analysts predict that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently bought a new position in Cyclerion Therapeutics stock. Two Sigma Investments LP bought a new stake in shares of Cyclerion Therapeutics, Inc. (NASDAQ:CYCN) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm bought 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned about 0.40% of Cyclerion Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 75.62% of the company’s stock.

About Cyclerion Therapeutics

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.